Read More Analyst Ratings News Price Target RBC Capital Maintains Sector Perform on Ovintiv, Raises Price Target to $58 By Benzinga Newsdesk November 10, 9:30 AM RBC Capital analyst Greg Pardy maintains Ovintiv (NYSE:OVV) with a Sector Perform and raises the price target from $57 to $58. OVV
Read More Biotech Eurozone General Markets News Ultragenyx Receives European Commission Decision For Evkeeza Expanded Indication In Children Aged 5 Years And Older With Homozygous Familial Hypercholesterolemia By Benzinga Newsdesk December 18, 9:08 AM Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that the European Commission (EC) has extended the approval of Evkeeza® (evinacumab) as an adjunct to diet and other lipid-lowering therapies to treat RARE
Read More Analyst Color Analyst Ratings News Price Target Reiteration Tech Executive Departure Not A Worry At Zscaler As Products ‘Sizzle,’ Analyst Says With ‘Strong Buy’ Rating On The Stock By Anusuya Lahiri October 11, 3:10 PM Needham analyst Alex Henderson reiterated a Strong Buy on Zscaler, Inc (NASDAQ:ZS) with a $210 price target. His pre-QP call with ZS… AMZN
Read More M&A News Activision insiders Fret $69B Microsoft Merger Could Fall Apart By Charles Gross November 6, 5:51 PM -NY Post https://nypost.com/2022/11/06/activision-insiders-fret-69b-microsoft-merger-could-crumble/ ATVI